Completed PHASE3 INTERVENTIONAL 2-arm NCT00172042

A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)

A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer

Sponsor: Novartis Pharmaceuticals

Conditions Non-Small-Cell Lung Cancer

Interventions Zoledronic acid 4 mg

Updated 6 times since 2017 Last updated: Apr 13, 2015 Started: Mar 31, 2005 Primary completion: May 31, 2010 Completion: Jun 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Non-Small-Cell Lung Cancer, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 6 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

's-Hertogenbosch, Netherlands , Aberdeen, United Kingdom , Alicante, Spain , Amsterdam, Netherlands , Athens, Greece , Bangkok, Thailand , Beijing, China , Bergamo, Italy , Berlin, Germany , Budapest, Hungary and 59 more locations